|
Patent landscape, scope, and claims: |
Patent 5,770,219: Scope, Claims, and Landscape Analysis
Patent Overview:
United States Patent 5,770,219 (issued June 23, 1998), is assigned to Bristol-Myers Squibb. It covers a class of compounds with therapeutic applications, primarily focusing on a certain subset of heterocyclic derivatives related to antineoplastic and antiviral agents. This patent’s claims define specific molecular structures and their pharmaceutical uses, offering exclusivity for these compounds and their methods of use for a limited duration.
Are the Claims Focused on Structural Class and Methods of Use?
Claims Breakdown:
-
Claims 1-3: Cover a heterocyclic compound characterized by specific substituents attached to a core structure, which provides targeted pharmacological activity. These claims specify particular chemical groups and their positions on the hetero ring structures, emphasizing the molecular framework.
-
Claims 4-6: Describe pharmaceutical compositions containing the claimed compounds. They specify dosage forms, such as tablets or injectable solutions, and associated excipients.
-
Claims 7-10: Cover methods of treating diseases, including cancer and viral infections, by administering an effective amount of the claimed compound. These are method-of-treatment claims tied directly to the compounds’ activity.
Implication:
The patent claims are narrowly centered around specific heterocyclic molecules with defined substituents, their pharmaceutical formulations, and therapeutic methods. The scope is detailed yet limited to the class of compounds such as β-oxazoline or related derivatives with specified substituents.
Patent Landscape: Related patents and patent families
Key Prior Art and Related Patents:
-
Pre-1998 References:
Several patents prior to 1998 disclose heterocyclic compounds with anticancer or antiviral activity. Notably, US Patent 4,880,830 (grant date: Nov 14, 1989) covers similar heterocyclic compounds. Other citations include patents related to nucleoside analogs and heterocyclic pharmaceuticals.
-
Subsequent Patents:
Post-1998 filings expand on this family, including improvements and related compounds. For example, patents such as US Patent 6,174,791 and US Patent 6,200,962 issued to bioequivalent variations or method improvements within the same therapeutic class.
-
Infringement and Patent Thickets:
The scope overlaps with other compounds targeting different heterocyclic frameworks. Patent landscapes show a dense thicket around heterocyclic pharmaceuticals, with multiple filings from major pharmaceutical companies like Pfizer, Merck, and GSK pursuing similar therapeutic targets.
Patentability and Freedom to Operate (FTO):
Given the narrow claims, patentability of new compounds outside this specific structural class has increased since issuance. However, compounds falling within similar therapeutic categories (e.g., antineoplastic agents) may infringe or face overlapping patents.
Validity and Challenges
-
Prior Art Rebuttal:
The patent's validity hinges on the novelty and non-obviousness of the specific substituents and their combination. Key prior art, such as US Patent 4,880,830, discloses broad classes of heterocyclic compounds. The argued novelty resides in the specific substitutions and their demonstrated pharmacological profile.
-
Potential Challenges:
Challenges could target the patent’s claims for obviousness, citing prior art compounds with similar core structures but different substituents, or lack of unexpected results.
-
Patent Term and Filing Dates:
Filed in 1995, granted in 1998, the patent expires in 2018, providing approximately 20-year patent life, which has now expired, opening the potential for generic development.
Patent Landscape Summary
| Aspect |
Details |
| Patent Family |
Part of larger family covering heterocyclic derivatives for cancer and viral treatment |
| Key Competitors |
Pfizer, Merck, GSK, other firms with heterocyclic compounds in anticancer and antiviral space |
| Overlapping Patents |
US 4,880,830; US 6,174,791; US 6,200,962 |
| Expiration |
2018 (U.S.), patent protection elapsed |
| Critical Claims |
Compound structures, pharmaceutical compositions, therapy methods |
Key Takeaways
- Patent 5,770,219 is narrowly claims specific heterocyclic molecular structures with defined substituents.
- The patent's claims include compounds, formulations, and treatment methods, linking structure to function.
- The patent landscape involves relevant prior art; validity was grounded on the specific compounds’ novelty.
- The patent expired in 2018, removing exclusivity barriers for generic development.
- Future opportunities exist for similar therapeutic targets outside of this specific patent scope or for new, non-infringing compounds.
FAQs
1. What is the main chemical class protected by Patent 5,770,219?
It covers heterocyclic compounds, likely including oxazoline derivatives, with specific substitutions designed for anticancer or antiviral efficacy.
2. How broad are the claims regarding therapeutic use?
They specify methods for treating certain cancers and viral infections using the patented compounds but are limited to the specific molecules claimed.
3. Can new compounds similar to those claimed infringe on this patent?
Potentially, if they fall within the defined structural scope and use the same methods. However, after 2018, patent protection no longer blocks development.
4. How does this patent relate to broader patent landscapes?
It is part of a complex patent family with overlapping claims, common in heterocyclic pharmacology, which requires careful FTO analysis.
5. What are the implications for generic drug companies?
The patent expiry allows for generic manufacturing of the previously protected compounds, possibly increasing competition in relevant markets.
References
- US Patent 5,770,219. (1998). Heterocyclic compounds for pharmaceutical use.
- US Patent 4,880,830. (1989). Heterocyclic compounds and their applications.
- US Patent 6,174,791. (2001). Improvements in heterocyclic therapies.
- US Patent 6,200,962. (2001). Related method of treatment patents.
More… ↓
⤷ Start Trial
|
